Welcome to our dedicated page for RVLP news (Ticker: RVLP), a resource for investors and traders seeking the latest updates and insights on RVLP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RVLP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RVLP's position in the market.
RVL Pharmaceuticals plc (Nasdaq: RVLP) reported preliminary first quarter 2022 net sales of UPNEEQ at approximately $5.9 million, marking a 90% increase from Q4 2021. The company reaffirms its fourth quarter 2022 sales guidance of $20 to 25 million. UPNEEQ, the first FDA-approved ophthalmic solution for blepharoptosis, received a ‘Best in Innovation’ award from New Beauty. CEO Brian Markison highlighted strong sales momentum and growing interest from medical aesthetic practices, indicating significant market potential for UPNEEQ.
RVL Pharmaceuticals reported fourth quarter 2021 UPNEEQ sales of $3.1 million, a 39% increase over Q3. Full year revenues reached $17.5 million, reflecting a 37% decline compared to 2020. The company anticipates Q1 2022 UPNEEQ sales between $5.5 - 6.0 million and reaffirmed Q4 2022 guidance at $20 - 25 million. A recent license agreement amendment is expected to generate $20 million in non-dilutive funding. The net loss narrowed to $19.7 million from $51.8 million in Q4 2020, while adjusted EBITDA loss improved to $15.2 million.
RVL Pharmaceuticals plc will announce its 2021 Q4 and full-year financial results on March 30, 2022, after U.S. market close. The Company will also provide updates on its first-quarter 2022 Medical Aesthetic launch. The conference call with key executives will be held at 4:30 p.m. ET on the same day. RVL is focused on developing products for underserved patient populations, currently commercializing UPNEEQ (oxymetazoline hydrochloride ophthalmic solution), 0.1%. For further details, investors can visit the Company's website.
RVL Pharmaceuticals plc (Nasdaq: RVLP), a specialty pharmaceutical company, announced its participation in the Barclays Global Healthcare Conference 2022. Key executives, including CEO Brian Markison, COO James Schaub, and CFO Andrew Einhorn, will present on March 16, 2022, at 11:15 a.m. ET. The presentation will be available via a webcast, accessible on the company’s website afterward. RVL focuses on developing products for underserved patient populations, with a subsidiary dedicated to ophthalmic and medical aesthetics.